The fate of bacillus Calmette-Guerin after intravesical instillation.
OBJECTIVE
Long-term activation of immunocompetent cells of the bladder wall as well as case reports of systemic infections some months or years after intravesical bacillus Calmette-Guerin (BCG) therapy imply that mycobacteria may persist in the body. Therefore. we investigated the fate of BCG in patients after uncomplicated intravesical instillation therapy.


METHODS
A total of 49 patients were included in the study, from whom various numbers of specimens were used for mycobacterial culture and molecular biological detection techniques. In 23 patients who received a total of 128 instillations urine, sputum, venous blood and bladder biopsies were screened for BCG by acid-fast staining and culture at different times before and after instillation. From 16 of the 23 patients and from an additional 26 a total of 180 bladder biopsies obtained at intervals 3 to 30 months after instillation were screened for mycobacterial 16S ribosomal DNA by a nested polymerase chain reaction protocol.


RESULTS
No viable BCG was found in venous blood or in 127 of 128 sputum specimens before and 2 hours after instillation. Two of 56 bladder biopsies were culture positive. In urine BCG was detected in 96.4% of the specimens after 2 hours and in 67.9% after 24 hours after instillation. The number of positive specimens decreased and it was 27.1% on day 7 immediately before the next instillation. In 14 of 44 bladder biopsies (31.8%) mycobacterial ribosomal DNA was found within 1 week after the sixth instillation. A positive polymerase chain reaction was evident up to 24 months in between 4.2% and 37.5% of the investigated biopsies. After 30 months no ribosomal DNA was evident in the 6 samples available for testing.


CONCLUSIONS
Nontraumatic intravesical instillation of BCG is not accompanied by systemic mycobacterial spread. Local persistence during the instillation course is evident since viable BCG is commonly found in the urine. Long lasting and persistent BCG DNA in the bladder wall may account for long-term immuno-activation. However, the remaining BCG may be a possible source of late systemic infections.
Durek
C
C
Department of Urology, Medical University of Lübeck, National Reference Center for Mycobacteria, Germany.
Richter
E
E
Basteck
A
A
Rüsch-Gerdes
S
S
Gerdes
J
J
Jocham
D
D
Böhle
A
A
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000627:therapeutic use; D016470:Bacteremia; D004269:DNA, Bacterial / Q000032:analysis; D004275:DNA, Ribosomal / Q000032:analysis; D006801:Humans; D007167:Immunotherapy; D009163:Mycobacterium bovis / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction; D013183:Sputum / Q000382:microbiology; D001743:Urinary Bladder / Q000382:microbiology; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014556:Urine / Q000382:microbiology
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D004269:DNA, Bacterial; D004275:DNA, Ribosomal